Alkermes Inc Stock as Institutional Investors Enter

October 13, 2017 - By Kurt Siggers

 Alkermes Inc Stock  as Institutional Investors Enter

Sentiment for Alkermes Inc (NASDAQ:ALKS)

Alkermes Inc (NASDAQ:ALKS) institutional sentiment increased to 1.12 in Q2 2017. Its up 0.01, from 1.11 in 2017Q1. The ratio has improved, as 118 hedge funds opened new or increased holdings, while 105 sold and reduced positions in Alkermes Inc. The hedge funds in our partner’s database reported: 143.16 million shares, up from 140.52 million shares in 2017Q1. Also, the number of hedge funds holding Alkermes Inc in their top 10 holdings decreased from 3 to 2 for a decrease of 1. Sold All: 33 Reduced: 72 Increased: 77 New Position: 41.

Alkermes plc is a biopharmaceutical company. The company has market cap of $7.73 billion. The Firm is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. It currently has negative earnings. The Firm has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

The stock decreased 0.08% or $0.04 during the last trading session, reaching $50.29. About 384,813 shares traded. Alkermes Plc (NASDAQ:ALKS) has risen 47.50% since October 13, 2016 and is uptrending. It has outperformed by 30.80% the S&P500.

Investors wait Alkermes Plc (NASDAQ:ALKS) to report on November, 1. its quarterly earnings Wall Street analysts expect $-0.15 EPS, up $0.10 or 40.00 % from last year’s $-0.25 same quarter earnings. Alkermes Plc’s Wall Street analysts see 15.38 % negative EPS growth, taking into account the $-0.13 EPS reproted in the previous quarter,

Meditor Group Ltd holds 8.99% of its portfolio in Alkermes Plc for 1.03 million shares. Opus Point Partners Management Llc owns 42,623 shares or 2.27% of their US portfolio. Moreover, Jag Capital Management Llc has 2.19% invested in the company for 188,682 shares. The New York-based Roanoke Asset Management Corp Ny has invested 2.09% in the stock. Kelly Lawrence W & Associates Inc Ca, a California-based fund reported 118,100 shares.#img1#

Alkermes Plc (NASDAQ:ALKS) Ratings Coverage

Ratings analysis reveals 73% of Alkermes’s analysts are positive. Out of 11 Wall Street analysts rating Alkermes, 8 give it “Buy”, 0 “Sell” rating, while 3 recommend “Hold”. The lowest target is $35 while the high is $85. The stock’s average target of $61.40 is 22.09% above today’s ($50.29) share price. ALKS was included in 26 notes of analysts from September 1, 2015. The firm earned “Hold” rating on Thursday, July 27 by Leerink Swann. Leerink Swann maintained Alkermes Plc (NASDAQ:ALKS) on Friday, October 21 with “Outperform” rating. As per Thursday, January 21, the company rating was downgraded by JP Morgan. The firm has “Market Perform” rating by Leerink Swann given on Tuesday, June 13. The stock of Alkermes Plc (NASDAQ:ALKS) earned “Hold” rating by Cantor Fitzgerald on Thursday, July 27. Morgan Stanley upgraded it to “Overweight” rating and $85 target in Tuesday, September 1 report. Jefferies maintained it with “Buy” rating and $62 target in Friday, July 29 report. As per Friday, January 22, the company rating was maintained by UBS. The stock has “Overweight” rating by JP Morgan on Friday, October 21. The firm has “Buy” rating by Jefferies given on Thursday, August 24.

More news for Alkermes Plc (NASDAQ:ALKS) were recently published by: Streetinsider.com, which released: “Alkermes plc (ALKS) Says Patients Switched to its ARISTADA Showed Significant …” on September 18, 2017. Seekingalpha.com‘s article titled: “Alkermes Preliminary Phase 3 Data Leaves A Welcomed Impression” and published on July 05, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.